ArticleBMC endocrine disorders2026
Associations between cholesterol, high-density lipoprotein, and glucose index and hyperuricemia in patients with diabetes.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundHyperuricemia (HUA) is closely linked to glycolipid metabolism disorder. The Cholesterol, High-Density Lipoprotein, and Glucose (CHG) index, an innovative composite glucolipid index, has been suggested as a potential diagnostic indicator for type 2 diabetes mellitus (T2DM). However, the associations between CHG and HUA in T2DM patients remain unknown. The purpose of this study was to elucidate the relationship between CHG and the risk of HUA in individuals with diabetes.
methodsA total of 1908 inpatients with T2DM between 2023 and 2024 were cross-sectionally assessed. The correlation between CHG and the risk of HUA was evaluated with multiple logistic and linear regression model, restricted cubic spline (RCS) method, and subgroup analysis.
resultsThe prevalence of HUA was 23.43% among diabetic patients in our study. In adjusted logistic regression models, CHG and HUA showed an independent positive connection (OR = 1.77, 95% CI = 1.39, 2.26; P < 0.001). Specifically, the odds of HUA prevalence were 1.03 times greater for patients in the highest quartile of CHG compared to those in the lowest quartile (OR = 2.03, 95% CI = 1.39, 2.97; P for trend < 0.001). This relationship was consistent in adjusted linear regression models. RCS analysis further exhibited a linear correlation between CHG and HUA. Subgroup analyses showed a more significant positive correlation among patients with age < 60 years old, body mass index (BMI) ≥ 25 kg/m² or 60 ≤ estimated glomerular filtration rate (eGFR) < 90 mL/min/1.73 m² (P < 0.05 for interaction). Significant interactions were also observed between CHG and HUA in the hypertension and hyperlipidemia subgroups.
conclusionsThere is a clear linear correlation between CHG index and HUA in T2DM patients. The CHG index may be a novel glucolipid index for the potential risk assessment of HUA, although further prospective studies are needed for verification. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.